Zhenghai biology: "active biological bone" has entered the state of "main review"
Financial Associated Press, November 29 - Zhenghai biology announced that the company's product "active biological bone" has recently completed the submission of "Supplementary information" of the product in accordance with the relevant requirements of the "information supplementary notice" of the medical device technical evaluation center of the State Drug Administration ("State Drug Administration") for the technical evaluation stage of the product, and entered the state of "main review".
This text is a result of machine translation.
Related companies：
Briefing May 19, 2022 11:34 AM
· Financials
The index recovered, and the gem index and Shanghai index once turned red
In-depth
Technology
AI Is Revolutionizing Decision-making
This article focuses on the market dynamics, applications, the industry ecosystem and future opportunities and challenges. Specifically, the article mainly analyses these complex issues through the in-depth case study of Youhualin, with unique insights from the industry expert.
Feb 06, 2023 11:35 PM
Donghua Technology: pre winning the EPC project of ammonium dihydrogen phosphate project for battery
Jan 05, 2023 07:33 PM
Nov 16, 2022 05:19 PM
Nov 10, 2022 02:39 PM
Nov 08, 2022 08:32 AM
Briefing Dec 20, 2021 08:58 AM
Bufeng international calls out the list of Hong Kong stocks under Shenzhen Hong Kong stock connect
Technology
Overwhelming ChatGPT Will Drive Strong Long-term Growth in Chip Market
At the end of November last year, ChatGPT became the fastest-growing consumer application in history upon its launch, with more than 1 million registered users in just 5 days and more than 100 million after two months.
Yesterday 12:05 PM
Briefing Oct 18, 2021 07:48 AM
· Financials
Public REITs will be expanded, and three new products have been accepted
Briefing Oct 15, 2021 07:32 AM
· Financials
The 2021 Financial Street forum annual meeting will be held in Beijing in late October
Healthcare
Dynamic Biosystems Snags Nearly CNY 100 Mn in Series A+
Dynamic Biosystems is a single cell and space multi-omics technology platform enterprise. The company focuses on exploring the huge potential in the fields of precision medicine of tumor, eugenics and fertility, and drug discovery, and is committed to promoting precision medicine to the era of single cell and space omics, helping life science and clinical medicine.
Feb 06, 2023 07:25 PM
Briefing Jul 11, 2021 04:31 PM
Boteng: net profit in the first half of the year increased by 60% - 70% year on year
Briefing Jul 07, 2021 10:09 PM
· Consumer Staples
Yuexiu Fengxing agriculture and animal husbandry signed a contract with Jiangsu Donghe group for the whole industry chain cooperation project of one million pigs
See more
Read next
Insight
In-depth
Insight
In-depth
Insight
In-depth
Consumer Discretionary
GeerTop: China's Camping Market Growth Expected to Slow
Feb 02, 2023 12:01 PM
Insight
In-depth
Healthcare
Chinese Company Turned the Tables on Domestic Cell Culture Media Market
Feb 02, 2023 10:45 AM